Refine by
Malaria Articles & Analysis
58 news found
Boston: Microneedle technology, driven by high demand in dermatologic procedures and its versatile applications in drug delivery, vaccine administration, and disease diagnostics, faces challenges in its complex manufacturing process. Ongoing research and numerous products in development make this market dynamic for newcomers entering the field. “According to the latest BCC Research study, ...
ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the Vaccines Summit 2022 in Washington DC on October 11-13. Founder of ImmunAdd, Pi-Hui Liang, said “My team and I were delighted to attend the Vaccines Summit, an internationally renowned academic conference, where we presented a ...
The published research details how this platform was used to express a malaria protein antigen that can be delivered intranasally and later boosted with a simple oral booster. Treated mice demonstrate protection against subsequent malaria challenge. The low cost and scalability of Lumen’s production platform, coupled with easy, needle-free administration, ...
The Acuitas team is currently working on therapeutics focused on addressing cancer, HIV/AIDS, rabies, tuberculosis, malaria and other serious ...
“Ready access to this life-saving drug is such an important tool in the global fight against malaria. The additional funding we have received will enable us to translate a robust technology built with our BioAssemblyLineTM cell factory engineering platform into a fully scaled process.” A key time to beat malaria… Malaria ...
The Acuitas team is currently working on therapeutics focused on addressing cancer, HIV/AIDS, rabies, tuberculosis, malaria and other serious ...
ImmunAdd’s next-generation Saponin-based adjuvant IA-05 induced both humoral and cellular immunities in various vaccines, including those against COVID-19, influenza, and cancer. IA-05 is accessible via total chemical synthesis and does not rely on extracts from Quillaja Saponaria or any other tree. ImmunAdd is undertaking the development of IA-05 in collaboration with several biopharma ...
” Half of Malawians are under the age of 15 and malaria remains a leading cause of death among children under the age of 5. Through a research partnership with the Mercy James Centre, Michigan State University procured a Hyperfine Swoop® portable MRI systemTM to facilitate critical research on cerebral malaria—the most severe form of the ...
Kephera scientists will work with collaborators at the National Institute of Malaria, Parasitology and Entomology in Vietnam, the country’s leading institution for research on human pathogenic parasites, and the Hanoi University of Public Health. ...
Additionally, in 2020, the foundation awarded a $4.2 million grant to Exscientia to identify new innovative treatments for malaria and tuberculosis – two of the world’s leading infectious disease killers – as well as new medicines for non-hormonal contraception. ...
In addition, participants vaccinated with R21/Matrix-M showed high titers of malaria-specific anti-NANP antibodies 28 days after the third vaccination, which were almost doubled with the higher adjuvant dose. ...
ByNovavax
Artesunate for Injection 110 mg, powder and solvent for solution is launching in the U.S. for initial treatment of severe malaria in adult and pediatric patients. From 2007 until today, the product was available in the U.S. only through an expanded access investigational new drug (IND) program managed by the Centers for Disease Control and Prevention (CDC). ...
Draft PR Notice 2020-X describes the groups of pests and their potential impact on public health as follows: Arthropods: The listed arthropods may cause asthma or trigger allergies, contaminate food, irritate skin, cause direct injury, or carry diseases such as epidemic typhus, trench fever, epidemic relapsing fever, malaria, encephalitis (St. Louis, Eastern, Western, West ...
“Atomwise’s expertise in AI drug discovery has the potential to further enhance malaria drug discovery,” said Dr. Timothy Wells, Chief Scientific Officer, Medicines for Malaria Venture (MMV). ...
“After proving our technology in malaria detection, it became overwhelmingly clear to us that the CBC, the world’s most common blood test, is where we’d make the most impact,” said Sarah Levy, Sight’s CTO, following the series C announcement. ...
Artesunate for Injection 110 mg, powder and solvent for solution is approved by FDA for initial treatment of severe malaria in adult and pediatric patients. Artesunate for Injection is in a group of drugs known as “artemisinin derivatives” and is on the World Health Organization Model List of Essential Medicines. ...
In September 2019, ARTES and Australian Burnett Institute published data on the efficient production of malaria vaccine candidates using virus-like particles (eVLP) produced with ARTES’ METAVAX® platform presenting malaria transmission-stage antigens, which were capable of inducing transmission-blocking antibodies ...
A team from the University of Camerino in Italy, recently used LC-MS/MS to identify killer toxins to discover new opportunities for controlling Malaria - a deadly infectious disease common in a number of tropical and subtropical countries. Malaria is not caused by a virus or bacteria but is spread by parasites known as Plasmodium. ...
With the funds from the foundation, Sirenas will accelerate the use of ATLANTIS™, including the integration of machine learning approaches, to identify therapeutic candidates to treat widespread infectious diseases including tuberculosis and malaria. "Sirenas is honored to be a long-time recipient of Bill & Melinda Gates Foundation funding to support breakthrough drug ...
BySirenas
Osivax pipeline is composed of a malaria vaccine candidate currently in phase I clinical trial, an influenza vaccine candidate expected to enter in phase I in early 2018, and other vaccine & immunotherapy candidates in research stage. ...